menu search

BIVI / Leqembi approval offers renewed hope for novel Alzheimer's disease treatments

Leqembi approval offers renewed hope for novel Alzheimer's disease treatments
US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated with Alzheimer's disease. Developed by Japanese drug-maker Eisai and comarketed with Biogen Inc (NASDAQ:BIIB), the American pharmaceutical giant, the FDA's endorsement paves the way for Medicare and other insurance plans to cover the treatment for individuals with mild dementia and early symptoms of Alzheimer's disease. Read More
Posted: Jul 10 2023, 16:43
Author Name: Proactive Investors
Views: 091998

BIVI News  

BioVie says blinded data points to hopeful Alzheimer's treatment potential

By Proactive Investors
October 25, 2023

BioVie says blinded data points to hopeful Alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its more_horizontal

New Strong Buy Stocks for October 19th

By Zacks Investment Research
October 19, 2023

New Strong Buy Stocks for October 19th

INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023. more_horizontal

BioVie complements its Alzheimer's clinical research program with social impact initiatives

By Proactive Investors
September 26, 2023

BioVie complements its Alzheimer's clinical research program with social impact initiatives

What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is more_horizontal

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

By Proactive Investors
September 26, 2023

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in more_horizontal

BioVie presents Alzheimer's study data on patient's baseline characteristics

By Proactive Investors
September 11, 2023

BioVie presents Alzheimer's study data on patient's baseline characteristics

BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer more_horizontal

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

By Benzinga
September 6, 2023

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround

By Zacks Investment Research
August 30, 2023

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical m more_horizontal

Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

By Zacks Investment Research
August 28, 2023

Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with str more_horizontal


Search within

Pages Search Results: